22 Feb 2021

Type Announcement


1.    Introduction

Nova MSC Berhad (“NovaMSC” or “Company”) wishes to inform that its wholly-owned subsidiary, NovaHEALTH Pte Ltd (“NH”) has on 22 February 2021 entered into a Loan Agreement with EyRIS Pte Ltd (“EyRIS”), a 42% owned subsidiary of NH, to grant and/or make available cash advances to EyRIS (“Loan”) on a clean basis.

Pursuant to the Loan Agreement, NH agree to grant and/or make available a cash advance of up to Singapore Dollar One Million (SGD1,000,000 [approximately RM 3.05 million]) to EyRIS upon a cash call by EyRIS.


2.    Information on NH and EyRIS

2.1    Information of NH

NH was incorporated in Singapore and is a wholly-owned subsidiary of NovaMSC.  Its principal activities are those relating to the provision of e-business solutions for the healthcare industry.


2.2    Information of EyRIS

EyRIS was incorporated in Singapore in 2018 and is a 42% owned subsidiary of NH. EyRIS has a licence to market SELENA+, an intelligent deep learning system that performs automated retinal photo analysis to detect retinopathy and systemic complications in diabetic patients.


3.      Salient Features of the Loan Agreement

3.1    The Loan shall bear interest on the principal amount outstanding at any given time at the rate of 6.0% (six per centum) per annum. Interest shall be computed on the Loan on a daily basis and based on actual days elapsed and a year of 365 (three hundred and sixty-five) days.


3.2    The Loan is available to EyRIS for a period of six months (“Term”) and shall be automatically be renewed for a consecutive period of six months or in such manner or extended date as may be mutually agreed between all the parties.


3.3    The Loan shall be unsecured and rank pari passu with other present and future unsecured obligations.


3.4    NH may cancel the Loan forthwith and without any prior written notice in case of any of the following events, which constitute default by EyRIS:

(a)     failure by EyRIS to pay to the NH any interest due;

(b)    failure by EyRIS to comply with any other term or condition of this Agreement, and if such failure is capable of being remedied, the failure remains not remedied for more than 30 (thirty) days after NH gives notice thereof to EyRIS;

(c)     the appointment of a receiver over any material part of the assets or undertakings of EyRIS;

(d)    the occurrence of any other event which in the reasonable opinion of NH would have a materially adverse effect on EyRIS’s ability to comply with any of its obligations under the Loan Agreement; or

(e)     the transfer of EyRIS’s business (or any part thereof) to a third party outside the group of companies of which NH and EyRIS originally are part of.


4.      Rationale

The Loan provides EyRIS a working capital for its operations requirements and will be utilized for its operating expenditures, which shall include, but not limited to, staff cost, travelling, rental and other administrative expenses.


5.      Source of Fund

The Loan is fully financed from internally generated funds.


6.      Effects of the Loan

6.1    Issued Share Capital and Substantial Shareholders’ Shareholdings

The Loan will not have any effect on the issued share capital and the shareholdings of the substantial shareholders in the Company.


6.2    Earnings Per Share, Net Assets Per Share and Gearing

The Loan will not have any material effect on NovaMSC Group’s earnings per share and net assets per share for the current financial year. The Loan will not have any effect on the gearing of the NovaMSC Group for the current financial year.


7.      Risk Factors

The Board of Directors of the Company (“Board”) does not envisage any specific risk associated with the Loan, apart from default risk due to the general business risks faced by EyRIS.


8.      Interests of Directors, Major Shareholders and Persons Connected with Them

Save as disclosed below, none of the Directors and/or major shareholders of the Company and/or persons connected with them has any interest, direct or indirect, in the Loan.

Mr Lai Teik Kin is a Director of NovaMSC and NH. He is also a director and major shareholder of EyRIS.


9.      Approval Required

The Loan is not subject to the approval of the shareholders of NovaMSC nor from any relevant governmental authorities.


10.    Directors’ Statement

The Board (save for Mr Lai Teik Kin who has abstained from all deliberation and voting on the Loan), having considered all aspects of the Loan (including but not limited to the terms and the rationale), is of the opinion that the Loan is fair and reasonable, in the best interest of NovaMSC Group and is not detriment to NovaMSC Group and its shareholders.


11.    Related party transactions

The Loan is a provision of financial assistance under Rule 8.25 of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad (“AMLR”) and in view of the interests disclosed in Section 8 of this announcement, the Loan is deemed a related party transaction pursuant to Rule 10.08 of the AMLR.


12.    Estimated Timeframe for Completion

The Loan is expected to be disbursed before 31 March 2021.


13.    Highest Percentage Ratio

The highest percentage ratio applicable to the Loan pursuant to Rule 10.02(g) of the AMLR is 4.65%. In this regard, the approval of the shareholders of NovaMSC is not required for the Loan.


14.    Document for Inspection

A copy of the Loan Agreement will be made available for inspection at the Company’s registered office at No. 5-1, Jalan Radin Bagus 9, Bandar Baru Sri Petaling, 57000 Kuala Lumpur, Wilayah Persekutuan, Malaysia during normal business office hours from Monday to Friday (except public holidays) for a period of 3 months from the date of the announcement.


This announcement is dated 22 February 2021.

Comments are closed.